Clinical Trials Logo

Chemotherapy Effect clinical trials

View clinical trials related to Chemotherapy Effect.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05985551 Active, not recruiting - Breast Cancer Clinical Trials

Delayed SLND for Patients With Breast Cancer Undergoing Primary Systemic Treatment

MagNeo
Start date: January 1, 2020
Phase:
Study type: Observational

The goal of this study was to assess the feasibility of SLND by superparamagnetic iron oxide nanoparticles (SPIO) in patients with early breast cancer planned for primary systemic therapy (PST) and whether this is affected by the timeframe of SPIO administration. For this, patients with cN0/1 disease planned for PST received radioisotope as per routine on the day of surgery or the day before, and SPIO was injected in an extended timeframe, at any point from the day of surgery to before the induction of PST. The main points to investigate are: 1. If the SPIO detection rate and concordance to the radiosotope are affected by time of SPIO injection 2. If the nodal yield and the accuracy of the procedure are affected

NCT ID: NCT05728632 Active, not recruiting - Breast Cancer Clinical Trials

Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines

CONTROL
Start date: January 1, 2019
Phase: Phase 3
Study type: Interventional

As the cancer-related prognosis improves thanks to recent advances in cancer-targeted therapies, the prognostic burden of chemotherapy-related complications - including cardiotoxicity - is increasingly recognised. So far, the evidence supporting pharmacological preventive strategies in cardio-oncology has been inconsistent and conflicting, and there is a clear need for well-designed trials with novel interventions. In this study, by using cardiac magnetic resonance, the investigators want to assess if a commonly used beta-blocker with a unique pharmacological profile, i.e. nebivolol, can prevent cardiac dysfunction in patients with breast cancer or diffuse large B-cell lymphoma undergoing chemotherapy with anthracyclines.

NCT ID: NCT05452850 Active, not recruiting - Clinical trials for Congestive Heart Failure

Longitudinal Changes in Left and Right Ventricular Global Strain After Chemotherapy in Cardiac Light Chain Amyloidosis

Start date: August 11, 2022
Phase:
Study type: Observational

The purpose of this study to assess the longitudinal changes in left and right ventricular global strain after chemotherapeutic strategies in cardiac light chain amyloidosis.

NCT ID: NCT04872582 Active, not recruiting - Chemotherapy Effect Clinical Trials

Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study

Start date: July 29, 2021
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of PD-1 immune checkpoint inhibitor combined with bevacizumab in the treatment of metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy.

NCT ID: NCT04689529 Active, not recruiting - Breast Cancer Clinical Trials

Unnecessary Mastectomy Due to False Size Prediction by Preoperative Imaging Studies in Breast Cancer

PUMP
Start date: March 23, 2018
Phase: N/A
Study type: Interventional

- The surgical method for breast cancer is determined according to the size and location of the remaining lesions after prior chemotherapy. - There are many patients who were able to undergo partial resection when confirming the final results of patients who underwent total resection after prior chemotherapy. - Therefore, we would like to investigate whether it is effective to make decisions based on the results of pre-operative tests after prior chemotherapy.

NCT ID: NCT04586088 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure

Start date: May 5, 2020
Phase: Phase 2
Study type: Interventional

This is a prospective phase II clinical trial to evaluate the efficacy and safety of apatinib and camrelizumab in recurrent or metastatic nasopharyngeal carcinoma who failed at least the first-line treatment.

NCT ID: NCT04447092 Active, not recruiting - Pancreatic Cancer Clinical Trials

Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer

Start date: July 1, 2020
Phase: Phase 2
Study type: Interventional

This is an open-label, phase 2 study of Pembrolizumab in combination with chemotherapy in chemotherapy-naïve advanced pancreatic cancer

NCT ID: NCT04423731 Active, not recruiting - Chemotherapy Effect Clinical Trials

Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer

Start date: January 1, 2018
Phase:
Study type: Observational

This is a Norwegian prospective observational study that evaluates the resectability rate in patients with borderline resectable and locally advanced pancreatic cancer who received neoadjuvant chemotherapy in a population based cohort. Eligible patients are treated with neoadjuvant chemotherapy possibly followed by surgical exploration and resection. All Norwegian centres performing pancreatic surgery have agreed to collaborate in this trial. The assignment of the medical intervention is not at the discretion of the investigator, but follow the national Norwegian guidelines regarding diagnostic work up, oncological and surgical treatment and follow up.

NCT ID: NCT04405622 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.

Start date: May 30, 2020
Phase: Phase 2
Study type: Interventional

This is an open-label, single center, pilot trial to evaluate the safety and efficacy of toripalimab and gemcitabine in patients with recurrent or metastatic nasopharyngeal carcinoma.

NCT ID: NCT04298021 Active, not recruiting - Chemotherapy Effect Clinical Trials

DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer

Start date: June 25, 2020
Phase: Phase 2
Study type: Interventional

To assess the effect of AZD6738 and Durvalumab combination or AZD6738 and Olaparib combination in biliary tract cancer patients who have failed to 1st-line chemotherapy.